Financial Results Release, Management Changes, and Newly Issued Permits - Research Report on Valeant, Teva, Endo, Array, and Sequenom

NEW YORK, August 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo Health Solutions Inc. (NASDAQ: ENDP), Array BioPharma Inc. (NASDAQ: ARRY), and Sequenom, Inc. (NASDAQ: SQNM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals International, Inc. Research Report

On August 7, 2013, Valeant Pharmaceuticals International, Inc. (Valeant) reported its Q2 2013 financial results. Total revenues for Q2 2013 were $1.1 billion, up 33.6% YoY. The Company's Q2 2013 net income was $10.9 million, or $0.03 per diluted share, compared with a net loss of $21.6 million, or $0.07 per diluted share, in Q2 2012. J. Michael Pearson, Chairman and CEO of Valeant said, "We are particularly pleased with the performance of our Emerging Markets segment, which delivered organic growth of 14%." The Full Research Report on Valeant Pharmaceuticals International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

--

Teva Pharmaceutical Industries Ltd Research Report

On August 5, 2013, Teva Pharmaceutical Industries Ltd (Teva) announced the appointments of Ika Abravanel as Executive Vice President of Teva Corporate in Israel and Global Community Alliances, effective September 1, 2013, and of Mark Sabag as Group Executive Vice President of Human Resources at Teva, effective August 11, 2013. According to the Company, Abravanel and Sabag will serve on the Company's Executive Committee and will report to Dr. Jeremy Levin, President and CEO of Teva. The Full Research Report on Teva Pharmaceutical Industries Ltd - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

--

Endo Health Solutions Inc. Research Report

On August 6, 2013, Endo Health Solutions Inc. (Endo) reported its Q2 2013 financial results. In Q2 2013, the Company reported total revenues of $766.5 million, down 2.4% YoY. Q2 2013 adjusted net income came in at $166.3 million, or $1.42 per diluted share, compared with $154.2 million, or $1.27 per diluted share in Q2 2012. Rajiv De Silva, President and CEO of Endo said, "Our expense reduction efforts are on track to meet our objectives, we have made progress in the exploration of strategic alternatives for HealthTronics and our branded pharmaceutical discovery platform, and we have positive organic growth momentum within each of our core businesses." The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/059c_ENDP]

--

Array BioPharma Inc. Research Report

On August 7, 2013, Array BioPharma Inc. (Array) reported financial results for Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). Revenue for Q4 FY 2013 was $25.4 million, up 23% YoY. Net loss was $17.6 million, or $0.15 per share, compared with net loss of $8 million, or $0.09 per share, in Q4 FY 2012. For full-year FY 2013, the Company reported revenue of $69.6 million, down 18.3% YoY. Net loss for full-year FY 2013 was $61.9 million, or $0.57 per share, compared with net loss of $23.6 million, or $0.33 per share, in full-year FY 2012. "Array has made important progress over the past year generating data with ARRY-520 and ARRY-614 to inform pivotal trial decisions by the end of calendar 2013," said Ron Squarer, CEO of Array. "In July, we shared positive results from our Phase 2 study of ARRY-502 which demonstrated its potential to become the first new oral medication for asthma since Singular was approved 15 years ago." The Full Research Report on Array BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e048_ARRY]

--

Sequenom, Inc. Research Report

On August 5, 2013, Sequenom, Inc. (Sequenom) announced that the New York Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program (CLEP) has issued a clinical laboratory permit, which allows the Sequenom Center for Molecular Medicine's (Sequenom CMM) San Diego facility to provide the MaterniT21 PLUS test to healthcare professionals in New York. According to the Company, this permit is in effect since August 1, 2013. Further, the Company also announced that Sequenom CMM's CLIA laboratory in North Carolina has received accreditation by the College of American Pathologists (CAP), which establishes that the facility has met all the applicable standards required to provide quality laboratory services. "The New York licensure and approval process is a very detailed and complex evaluation by a regulatory body to ensure the accuracy and reliability of laboratory testing that is provided throughout New York State, and we believe the successful CLEP permit, in addition to the recent CAP accreditation in North Carolina, further validate the clinical, technical, and scientific merits of our industry-leading noninvasive prenatal technology," said Allan Bombard, M.D., Chief Medical Officer of Sequenom. The Full Research Report on Sequenom, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d291_SQNM]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner